Genmab (ADR)
Develops antibody medicines through partner royalties, co-commercialization, and a wholly owned oncology portfolio.
$33.25
After-hours close+0.03 (+0.09%)
At close$33.22(−2.58%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 16.68%Insiders —
Shares outstanding 613.94M · Float 606.43M · 98.8% free float
Institutions13F, as of Jun 30, 2026
304 holders · 102.42M shares · 50 new positions · 152 increased · 101 reduced · 35 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 13.13M | 2.14% | +5.17M | Aug 14, 2026 |
| Orbis Allan Gray Ltd | 11.37M | 1.85% | −1.56M | Aug 14, 2026 |
| AllianceBernstein L.P. | 8.64M | 1.41% | −912.3K | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 6.87M | 1.12% | +4.40M | Aug 14, 2026 |
| Deep Track Capital, LP | 5.65M | 0.92% | +1.99M | Aug 14, 2026 |
| Arrowstreet Capital, Limited Partnership | 4.98M | 0.81% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 4.67M | 0.76% | +134.7K | Aug 7, 2026 |
| Sofinnova Investments, Inc. | 4.05M | 0.66% | +3.29M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.60% | 3.71M | 13G | Apr 23, 2025 ↗ |
| Orbis Investment Management Ltd | 5.50% | 3.55M | 13G | May 15, 2026 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.